During the study and follow‐up period, 34 patients experienced PSA progression; 37 experienced radioclinical progression as defined by a ≥20% increase in the sum of the soft tissue lesion diameters during computed tomography, ≥2 new bone lesions on bone scan, or symptomatic progression (worsening pain aggravation or new cancer‐related symptoms); and 22 patients died. This evidence concerns the gene KLK3 and cancer.